Related Experiment Video
Updated: Jun 23, 2025

A Method for Measuring RNA N6-methyladenosine Modifications in Cells and Tissues
Published on: December 5, 2016
Insight into the regulatory mechanism of m6A modification: From MAFLD to hepatocellular carcinoma
Abstract:
In recent years, there has been a significant increase in the incidence of metabolic-associated fatty liver disease (MAFLD), which has been attributed to the increasing prevalence of type 2 diabetes mellitus (T2DM) and obesity. MAFLD affects more than one-third of adults worldwide, making it the most prevalent liver disease globally. Moreover, MAFLD is considered a significant risk factor for hepatocellular carcinoma (HCC), with MAFLD-related HCC cases increasing. Approximately 1 in 6 HCC patients are believed to have MAFLD, and nearly 40 % of these HCC patients do not progress to cirrhosis, indicating direct transformation from MAFLD to HCC. N6-methyladenosine (m6A) is commonly distributed in eukaryotic mRNA and plays a crucial role in normal development and disease progression, particularly in tumors. Numerous studies have highlighted the close association between abnormal m6A modification and cellular metabolic alterations, underscoring its importance in the onset and progression of MAFLD. However, the specific impact of m6A modification on the progression of MAFLD to HCC remains unclear. Can targeting m6A effectively halt the progression of MAFLD-related HCC? In this review, we investigated the pivotal role of abnormal m6A modification in the transition from MAFLD to HCC, explored the potential of m6A modification as a therapeutic target for MAFLD-related HCC, and proposed possible directions for future investigations.
Insights
Metabolic-associated fatty liver disease (MAFLD) is rising globally. This review explores how N6-methyladenosine (m6A) modification impacts MAFLD progression to liver cancer and its therapeutic potential.
Area of Science:
- Hepatology
- Molecular Biology
- Oncology
Background:
- Metabolic-associated fatty liver disease (MAFLD) incidence is increasing globally, linked to obesity and type 2 diabetes mellitus (T2DM).
- MAFLD affects over one-third of adults worldwide, becoming the most common liver disease.
- MAFLD is a significant risk factor for hepatocellular carcinoma (HCC), with a notable percentage of HCC cases arising directly from MAFLD without cirrhosis.
Purpose of the Study:
- To investigate the role of N6-methyladenosine (m6A) modification in the progression of MAFLD to HCC.
- To explore the potential of targeting m6A as a therapeutic strategy for MAFLD-related HCC.
- To identify future research directions concerning m6A in MAFLD-HCC transition.
Main Methods:
- Review of existing literature on m6A modification, MAFLD, and HCC.
- Analysis of studies linking aberrant m6A patterns to metabolic alterations and cancer development.
- Synthesis of current understanding regarding m6A's impact on MAFLD pathogenesis and HCC transformation.
Main Results:
- Abnormal m6A modification is closely associated with cellular metabolic dysregulation, contributing to MAFLD onset and progression.
- Evidence suggests a critical role for m6A in the direct transformation of MAFLD to HCC.
- The precise mechanisms by which m6A influences MAFLD-to-HCC transition require further elucidation.
Conclusions:
- Aberrant m6A modification is implicated in the progression of MAFLD to HCC.
- Targeting m6A pathways presents a promising therapeutic avenue for MAFLD-related HCC.
- Further research is warranted to fully understand and exploit m6A's role in MAFLD-associated liver cancer.
Related Concept Videos
Master Transcription Regulators
MicroRNAs
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Regulation of Expression at Multiple Steps
Nuclear Export of mRNA

